Drugs / HEC585
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05468346 | Jul → Aug 2022 | — | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07588646 | Jun → Nov 2021 | idiopathic pulmonary fibrosis | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05383131 | Jun → Nov 2021 | idiopathic pulmonary fibrosis | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04512170 | Jul 2020 → Aug 2021 | idiopathic pulmonary fibrosis | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03092102 | May 2017 → Feb 2019 | idiopathic pulmonary fibrosis | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05139719 | Feb 2023 → Dec 2026 expected | interstitial lung disease | Sunshine Lake Pharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05060822 | Jun 2021 → Jul 2025 overdue | idiopathic pulmonary fibrosis | Sunshine Lake Pharma Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07082842 | Oct 2025 → Jan 2031 expected | idiopathic pulmonary fibrosis | Sunshine Lake Pharma Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HEC585 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03092102 ↗ |
| Modality | Small molecule | “HEC585, a pyrimidone compound” NCT03092102 ↗ |
| Route | Oral | “multiple oral dose” NCT03092102 ↗ |